Abstract

CLC Number:

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2014/V11/I9/567

[1] 吴洪文.小剂量甲氨喋呤所致严重骨髓抑制二例[J].中国药物与临床,2007,10（7）：768-768.
[2] 藏贵明,龙南展,张昭馥,等.小剂量甲氨喋呤致严重急性骨髓抑制死亡一例报告[J].天津医药,2002,11（30）：649-649.
[3] 周惠琼,吴东海,马丽.短期小剂量甲氨喋呤导致严重不良反应临床分析[J].中华风湿病学杂志,2002,2（6）：135-138.
[4] 张毅,郭澄.对短期小剂量甲氨喋呤致不良反应病例的治疗与思考[J].中国药业,2011,19（20）：80-81.
[5] 常晓慧,向阳,成玉斌,等.甲氨喋呤治疗老年银屑病引起全血细胞减少致死1例[J].临床荟萃,2010,24（25）：2176-2176.
[6] 庄志.甲氨喋呤致老年类风湿关节炎重度骨髓抑制分析[J]现代中西医结合杂志,2009,18(1)：25-26.
[7] 刘燕湘.甲氨喋呤引起口腔溃疡、骨髓抑制致死亡1例[J].中国药物警戒,2012,4（9）：251.
[8] 吴建龙,田洁.甲氨喋呤过量致危及生命不良反应救治的药学监护[J].药品评价,2010,10（7）：52-55.
[9] 胡文倩,万淑芳,张赤.大剂量甲氨喋呤致患儿死亡2例[J].家庭用药,2000,6(19)： 604.
[10] 陆俊杰.小剂量甲氨蝶呤致严重不良反应1例[J].临床合理用药,2012,9(5)：6.
[11] 谢祥成,王鸣,赵宁.甲氨喋呤致慢性肾功能衰竭患者死亡1例[J].中国医师进修杂志,2007,8（30）：77.
[12] 张新才.甲氨喋呤鞘内注射致急性肺水肿死亡1例[J].潍坊医学院学报,1999,21（3）：188.
[13] Sinicina I, Mayr B, Mall G, et al. Deaths following methotrexate overdoses by medical staff[J].J of Rheumatol,2005,32(10):2009-2011.
[14] Moisa A, Fritz P, Benz D, et al. latrogenically-related, fatal methotrexate intoxication: A scrics of four cases [J].Forcnsic sci int,2006,156(2-3):154-157.
[15] Shprecher D, Frech T, Chin S, et al. Progressive multifocal Icu coencepha lopathy associated with lupus and methotrexate coverdose[J].Lupus,2008,17(11)：1029-1032.
[16] Malbora B, Ozyarek E, Kocum A I, et al. Delayed recognition of intrathecal methotrexate overdose[J].J pediatr Hematol oncol,2009,31(5):352-354.
[17] 尹国华,张开明,邓联北,等.小剂量MTX治疗银悄病引起全血细胞减少致死1例[J].中国皮肤性病学杂志,1995,9（3）： 162.
[18] 邓宪,张海峰,施云星,等.老年人外周血象的变化及意义[J].海军医学杂志,2004,25（2）：145-146.
[19] 邓蓉,沈爱宗,朱继业.甲氨喋呤的不良反应[J].安徽医药,2008,12（9）：876-877.
[20] Felson D T, Chernoff M, Andeerson J J, et al.The effect of age and renal fanction on the efficacy and toxicity of methotrexate in rheumatoid arthritis[J].Rheumatol,1995,22（2）:2218.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.